The new malaria vaccine, also known as RTS,S or by its brand name Mosquirix, was developed by GlaxoSmithKline. On Oct. 6, the World Health Organization endorsed the RTS,S vaccine.
Basic, everyday drugs can cost up to 20 to 30 times more in some poor countries than others, according to a new study released today by the Center for Global Development.